Switching to Biktarvy maintains viral suppression in people aged 65 or over
Recycling tenofovir better than switch to second-line zidovudine
People switching from TDF to TAF experience rising cholesterol levels
Low level detectable viral load while taking HIV treatment is associated with poorer medical outcomes
Delaying treatment changes when first-line ART fails costs lives, says South African study
Proviral DNA resistance testing allows treatment switches without viral rebound
Lipid increases after switching from TDF to TAF are reversible when treatment is changed back to TDF
Options for two-drug simplification expand
Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts
